BioCryst Pharmaceuticals | BCRX - Operating Expenses


BioCryst Pharmaceuticals reported $119.78M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Chugai Pharma JPY 180.73B 17.74B Jun/2026
Daiichi Sankyo JPY 489.64B 21.08B Jun/2026
DBV Technologies USD 47.9M 2.2M Mar/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Incyte USD 973.64M 4.65B Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novavax USD 126.2M 23.62M Dec/2025
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026